
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International has demonstrated positive sales growth in its Healthcare Systems & Technologies segment, with increases of approximately 6% and 2% year-over-year in the first two quarters of 2025, and forecasts suggesting continued, albeit modest, growth of around 4% and 2% for the latter half of the year. The acquisition of Hillrom has expanded Baxter's operational portfolio, enhancing its range of hospital-focused products and strengthening its competitive position in the medical supplies industry. Furthermore, pricing initiatives are projected to contribute around 100 basis points to sales growth for 2024 and 2025, indicating effective management in boosting revenue amidst challenging market conditions.
Bears say
Baxter International's outlook is negatively impacted due to a disappointing performance in the second quarter of 2025, where sales, margins, and earnings per share fell below consensus expectations. The company has experienced a challenging operational period from 2021 to 2023, characterized by both external factors and internal missteps, resulting in mixed quarterly results and negative guidance revisions. Additionally, gross margins of 40.7% and operating margins of 15.1% fell short of consensus estimates, reflecting sales softness, manufacturing inefficiencies, and an unfavorable product mix.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares